Identification | Back Directory | [Name]
Brivudine | [CAS]
69304-47-8 | [Synonyms]
BVDU BVDR BrVDU Helpin SC-38394 Brivudin BRIVUDINE Brivudine
BVdU Brivudine USP/EP/BP Bromovinyldeoxyuridine BROMOVINYLDEOXYURIDINE; BVDU 5-(2-Bromovinyl)-deoxy-uridine Brivudine(BroMovinyldeoxyuridine) (E)-(5)-BROMOVINYL-2-DEOXYURIDINE 5-(E)-(2-Bromovinyl)-2-deoxyuridine (E)-5-(2-BROMOVINYL)-2'-DEOXY-URIDINE (E)-5-(2-Bromovinyl)-2'-deoxyuridine > Uridine,5-[(1E)-2-broMoethenyl]-2'-deoxy- (E)-5-(2-Bromovinyl)-2'-deoxyuridine 5-[(E)-2-Bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione 5-((E)-2-bromovinyl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione BrivudineQ: What is
Brivudine Q: What is the CAS Number of
Brivudine Q: What is the storage condition of
Brivudine Q: What are the applications of
Brivudine | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C11H13BrN2O5 | [MDL Number]
MFCD00058585 | [MOL File]
69304-47-8.mol | [Molecular Weight]
333.14 |
Chemical Properties | Back Directory | [Melting point ]
165°C | [density ]
1.7800 (rough estimate) | [refractive index ]
1.6520 (estimate) | [storage temp. ]
2-8°C
| [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
8.37±0.10(Predicted) | [color ]
Off-White | [Water Solubility ]
Soluble in water and methanol. | [Merck ]
14,1378 | [InChIKey]
ODZBBRURCPAEIQ-CXYVBZRVSA-N |
Hazard Information | Back Directory | [Description]
(E)-5-(2-Bromovinyl)-2'-deoxyuridine is an thymidine analogue and acts as an anti-viral by inhibiting DNA plymerase. | [Chemical Properties]
White solid | [Uses]
It is used as pharmaceutical intermediate. | [Synthesis]
GENERAL STEPS: To a solution of (E)-5-(2-carboxyvinyl)-1-(2-deoxy-β-D-erythro-pentofuranosyl)pyrimidine-2,4(1H,3H)-dione (5.777 g, 19.37 mmol) in dimethylformamide (29 mL) was added K2CO3 (5.890 g, 42.61 mmol), and the suspension was stirred at room temperature for for 15 min. A solution of N-bromosuccinimide (3.655 g, 20.53 mmol) was added dropwise over a period of 30 min at 20 °C. After completion of the reaction, the resulting suspension was filtered and the solid was washed with DMF. The combined filtrate and washings were evaporated to dryness under vacuum and the residue was dissolved in methanol. Silica gel was added to this solution, the suspension was evaporated to dryness, and the solid was loaded onto the top of the column. Column chromatography using chloroform/methanol (92:8, v/v) as eluent gave a white solid (5.787 g, 71.9% yield). A white powder was obtained by recrystallization from water. The structure of the product was confirmed by 1H-NMR and 13C-NMR: 1H-NMR (DMSO-d6; 300 MHz) δ 11.59 (1H, bs, NH-3), 8.08 (1H, s, H-6), 7.25 (1H, d, 3J = 13.6 Hz, H-5B), 6.85 (1H, d, J = 13.6 Hz, H-5A) , 6.13 (1H, t, 3J = 6.5 Hz, H-1'), 5.29 (1H, bs, OH-3'), 5.13 (1H, bs, OH-5'), 4.24 (1H, m, H-3'), 3.79 (1H, m, H-4'), 3.66 (2H, m, H-5'), 2.51 (1H, m, H-2'), 2.14 (1H, m, H-2'); 13C-NMR (DMSO-d6; 75 MHz) δ 40.2 (C-2'), 61.3 (C-5'), 70.3 (C-4'), 84.8 (C-3'), 87.8 (C-1'), 108.9 (C-5B), 110.0 (C-5), 130.3 (C-5A), 149.6 , 162.1 (c-2, c-4). | [Enzyme inhibitor]
This halogenated nucleoside (FW = 333.14 g/mol), also known as brivudin
and 5-[ (E) -2-bromoethenyl]-2’-deoxyuridine, is an antiherpetic agent that
inhibits viral DNA polymerase. BvdU is a highly potent and selective
inhibitor of herpes simplex virus type 1 and varicella-zoster virus infections.
Target (s) : DNA polymerase, viral, via the 5’-triphosphate ; HSV-1
replication ; 5’ nucleotidases; dTMP kinase, or thymidylate kinase
; deoxynucleoside kinase, also alternative substrate; thymidine
kinase. | [in vivo]
At a dose of 125 mg once daily, brivudine has proved to be superior to aciclovir with respect to reducing the period of new blister production, and has shortened the duration of post-herpetic neuralgia[1]. | [References]
[1] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 24, p. 6663 - 6671 [2] RSC Advances, 2015, vol. 5, # 31, p. 24558 - 24563 [3] Patent: WO2005/12327, 2005, A2. Location in patent: Page/Page column 24-25 [4] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 20, p. 5640 - 5642 [5] Patent: US6653318, 2003, B1 |
|
|